A cancer vaccine targeted at epidermal growth factor (EGF) stimulated anti-EGF antibodies, reduced serum levels of EGF, and improved survival in a Cuban phase I study reported at a conference here on Friday.
Dr. Tania Crombet from Center of Molecular Immunology in Havana said the results of the trial have prompted a phase II study to be conducted in patients with non-small cell lung cancer in Cuba, the United Kingdom and Canada.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!